(Total Views: 273)
Posted On: 04/26/2017 7:52:46 AM
Post# of 23071
$PTIE financial results were posted - as well as some nice forward-looking statements:
"In addition, in the quarter ahead we expect to announce news and updates around our program in Alzheimer's Disease, which to date we have advanced primarily with funding from competitive, peer-reviewed grant awards."
Regarding REMOXY:
"We expect to complete these studies by year-end 2017"
//
In other news, I'm hoping that all of those with voting rights, cast their vote to approve the reverse-split in May -- we (well, I) don't want this to be bumped down to OTC....
Even still - expect some abnormal volume in May and possibly June surrounding their news of new developments/etc - and I might pick up a few more shares when/if it dips to around .70/.71 again, but otherwise, still holding onto these guys for their FDA approval.....
On the negative side - reading their February report gave me some chills, particularly with the risks that they have with some vendors (and already losing one). I surely hope that when the time comes to where they've received FDA approval, that they're on the fast-track with licensing or partnering with someone to sell it.. This puppy needs to move...
"In addition, in the quarter ahead we expect to announce news and updates around our program in Alzheimer's Disease, which to date we have advanced primarily with funding from competitive, peer-reviewed grant awards."
Regarding REMOXY:
"We expect to complete these studies by year-end 2017"
//
In other news, I'm hoping that all of those with voting rights, cast their vote to approve the reverse-split in May -- we (well, I) don't want this to be bumped down to OTC....
Even still - expect some abnormal volume in May and possibly June surrounding their news of new developments/etc - and I might pick up a few more shares when/if it dips to around .70/.71 again, but otherwise, still holding onto these guys for their FDA approval.....
On the negative side - reading their February report gave me some chills, particularly with the risks that they have with some vendors (and already losing one). I surely hope that when the time comes to where they've received FDA approval, that they're on the fast-track with licensing or partnering with someone to sell it.. This puppy needs to move...
(2)
(0)
